Literature DB >> 3316579

OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients.

G Goldstein1, A B Kremer, L Barnes, R L Hirsch.   

Abstract

The monoclonal antibody OKT3 was previously shown to be superior to conventional high-dose steroid therapy for reversal of acute rejection of renal allografts. Furthermore, OKT3 was effective in reversing acute renal or hepatic allograft rejection that was resistant to treatment with steroids, anti-thymocyte globulin, or both. Our analysis demonstrates that OKT3 is also effective in pediatric patients in reversing acute rejection of renal allografts (rescue treatment) or hepatic allografts (primary or rescue treatment).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316579     DOI: 10.1016/s0022-3476(87)80054-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case.

Authors:  Tomohide Hori; Justin H Nguyen; Shinji Uemoto
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

Review 2.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

3.  OKT3 induction in pediatric renal transplantation.

Authors:  S M Bartosh; A J Aronson; E E Swanson-Pewitt; J R Thistlethwaite
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

4.  Liver transplantation in children.

Authors:  R W Busuttil; P Seu; J M Millis; K M Olthoff; J R Hiatt; A Milewicz; B Nuesse; G el-Khoury; D Raybould; A Nyerges
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

Review 5.  Therapy for acute rejection in pediatric organ transplant recipients.

Authors:  Dominique Debray; Válerie Furlan; Véronique Baudouin; Lucile Houyel; Florence Lacaille; Christophe Chardot
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.